Cantargia AB (publ) is a biotech company that is developing an antibody-based cancer treatment, which aims to attack cancer cells and decrease the tumour inflammation. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, interleukin 1 receptor associated protein “IL1RAP”, in cancer stem cells in patients with leukemia that is not found in normal stem cells in the bone marrow. In preclinical studies (in vitro and in vivo) the antibody, targeted against IL1RAP, has been shown to have two potential mechanisms of action, which are complementary. The company has selected a product candidate for future studies in humans and development activities have been focused on non-small cell lung cancer and pancreatic cancer.